These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38920116)

  • 1. Development of Broad-Spectrum Nanobodies for the Therapy and Diagnosis of SARS-CoV-2 and Its Multiple Variants.
    He L; Wu Q; Zhang Z; Chen L; Yu K; Li L; Jia Q; Wang Y; Ni J; Wang C; Li Q; Zhai X; Zhao J; Liu Y; Fan R; Li YP
    Mol Pharm; 2024 Aug; 21(8):3866-3879. PubMed ID: 38920116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomics Platform Reveals Broad-Spectrum Nanobodies for SARS-CoV-2 Variant Neutralization.
    Zhang R; Huang L; Zhang X; Yu Y; Liang T; Wang H; Zhang X; Hu D; Wang B; Wang Y; Jiang J; Yu X
    J Proteome Res; 2024 May; 23(5):1559-1570. PubMed ID: 38603467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants.
    Xu J; Xu K; Jung S; Conte A; Lieberman J; Muecksch F; Lorenzi JCC; Park S; Schmidt F; Wang Z; Huang Y; Luo Y; Nair MS; Wang P; Schulz JE; Tessarollo L; Bylund T; Chuang GY; Olia AS; Stephens T; Teng IT; Tsybovsky Y; Zhou T; Munster V; Ho DD; Hatziioannou T; Bieniasz PD; Nussenzweig MC; Kwong PD; Casellas R
    Nature; 2021 Jul; 595(7866):278-282. PubMed ID: 34098567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2.
    Cornish K; Huo J; Jones L; Sharma P; Thrush JW; Abdelkarim S; Kipar A; Ramadurai S; Weckener M; Mikolajek H; Liu S; Buckle I; Bentley E; Kirby A; Han X; Laidlaw SM; Hill M; Eyssen L; Norman C; Le Bas A; Clarke J; James W; Stewart JP; Carroll M; Naismith JH; Owens RJ
    Open Biol; 2024 Jun; 14(6):230252. PubMed ID: 38835241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape.
    Mast FD; Fridy PC; Ketaren NE; Wang J; Jacobs EY; Olivier JP; Sanyal T; Molloy KR; Schmidt F; Rutkowska M; Weisblum Y; Rich LM; Vanderwall ER; Dambrauskas N; Vigdorovich V; Keegan S; Jiler JB; Stein ME; Olinares PDB; Herlands L; Hatziioannou T; Sather DN; Debley JS; Fenyö D; Sali A; Bieniasz PD; Aitchison JD; Chait BT; Rout MP
    Elife; 2021 Dec; 10():. PubMed ID: 34874007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Basis for Evasion of New SARS-CoV-2 Variants from the Potent Virus-Neutralizing Nanobody Targeting the S-Protein Receptor-Binding Domain.
    Sluchanko NN; Shcheblyakov DV; Varfolomeeva LA; Favorskaya IA; Dolzhikova IV; Korobkova AI; Alekseeva IA; Esmagambetov IB; Derkaev AA; Prokofiev VV; Zorkov ID; Logunov DY; Gintsburg AL; Popov VO; Boyko KM
    Biochemistry (Mosc); 2024 Jul; 89(7):1260-1272. PubMed ID: 39218023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
    Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
    Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies.
    He Q; An Y; Zhou X; Xie H; Tao L; Li D; Zheng A; Li L; Xu Z; Yu S; Wang R; Hu H; Liu K; Wang Q; Dai L; Xu K; Gao GF
    Med; 2024 May; 5(5):401-413.e4. PubMed ID: 38574739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody.
    Valenzuela Nieto G; Jara R; Watterson D; Modhiran N; Amarilla AA; Himelreichs J; Khromykh AA; Salinas-Rebolledo C; Pinto T; Cheuquemilla Y; Margolles Y; López González Del Rey N; Miranda-Chacon Z; Cuevas A; Berking A; Deride C; González-Moraga S; Mancilla H; Maturana D; Langer A; Toledo JP; Müller A; Uberti B; Krall P; Ehrenfeld P; Blesa J; Chana-Cuevas P; Rehren G; Schwefel D; Fernandez LÁ; Rojas-Fernandez A
    Sci Rep; 2021 Feb; 11(1):3318. PubMed ID: 33558635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses.
    Yang Y; Li F; Du L
    J Nanobiotechnology; 2024 May; 22(1):304. PubMed ID: 38822339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies.
    Güttler T; Aksu M; Dickmanns A; Stegmann KM; Gregor K; Rees R; Taxer W; Rymarenko O; Schünemann J; Dienemann C; Gunkel P; Mussil B; Krull J; Teichmann U; Groß U; Cordes VC; Dobbelstein M; Görlich D
    EMBO J; 2021 Oct; 40(19):e107985. PubMed ID: 34302370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening and optimization of shark nanobodies against SARS-CoV-2 spike RBD.
    Liu X; Wang Y; Sun L; Xiao G; Hou N; Chen J; Wang W; Xu X; Gu Y
    Antiviral Res; 2024 Jun; 226():105898. PubMed ID: 38692413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanobody repertoire generated against the spike protein of ancestral SARS-CoV-2 remains efficacious against the rapidly evolving virus.
    Ketaren NE; Mast FD; Fridy PC; Olivier JP; Sanyal T; Sali A; Chait BT; Rout MP; Aitchison JD
    Elife; 2024 May; 12():. PubMed ID: 38712823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models.
    Han Q; Wang S; Wang Z; Zhang C; Wang X; Feng N; Wang T; Zhao Y; Chi H; Yan F; Xia X
    Virol Sin; 2023 Oct; 38(5):787-800. PubMed ID: 37423308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced potency of an IgM-like nanobody targeting conserved epitope in SARS-CoV-2 spike N-terminal domain.
    Liu B; Liu H; Han P; Wang X; Wang C; Yan X; Lei W; Xu K; Zhou J; Qi J; Fan R; Wu G; Tian WX; Gao GF; Wang Q
    Signal Transduct Target Ther; 2024 May; 9(1):131. PubMed ID: 38740785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies.
    Kaewchim K; Glab-Ampai K; Mahasongkram K; Saenlom T; Thepsawat W; Chulanetra M; Choowongkomon K; Sookrung N; Chaicumpa W
    Viruses; 2023 May; 15(6):. PubMed ID: 37376552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries.
    Yuan TZ; Garg P; Wang L; Willis JR; Kwan E; Hernandez AGL; Tuscano E; Sever EN; Keane E; Soto C; Mucker EM; Fouch ME; Davidson E; Doranz BJ; Kailasan S; Aman MJ; Li H; Hooper JW; Saphire EO; Crowe JE; Liu Q; Axelrod F; Sato AK
    MAbs; 2022; 14(1):2002236. PubMed ID: 34967699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529).
    Lu Y; Li Q; Fan H; Liao C; Zhang J; Hu H; Yi H; Peng Y; Lu J; Chen Z
    Int J Nanomedicine; 2023; 18():353-367. PubMed ID: 36700149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
    Huo J; Le Bas A; Ruza RR; Duyvesteyn HME; Mikolajek H; Malinauskas T; Tan TK; Rijal P; Dumoux M; Ward PN; Ren J; Zhou D; Harrison PJ; Weckener M; Clare DK; Vogirala VK; Radecke J; Moynié L; Zhao Y; Gilbert-Jaramillo J; Knight ML; Tree JA; Buttigieg KR; Coombes N; Elmore MJ; Carroll MW; Carrique L; Shah PNM; James W; Townsend AR; Stuart DI; Owens RJ; Naismith JH
    Nat Struct Mol Biol; 2020 Sep; 27(9):846-854. PubMed ID: 32661423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.